Basic Pharma

Executive Summary

Basic Pharma is a Netherlands-based Contract Development and Manufacturing Organization (CDMO) that has been providing end-to-end GMP-compliant services since 2005. The company specializes in small molecule drug development and manufacturing, from API to finished dosage forms, and offers analytical testing, regulatory consultancy, and generic product development. Its integrated service model and strategic location in Amsterdam position it as a reliable partner for pharmaceutical and biotech companies seeking high-quality outsourcing solutions within Europe. Basic Pharma is privately held and has established a reputation for technical expertise and regulatory compliance, serving a diverse client base in the competitive CDMO market. The company is now expanding its capabilities to include biologicals manufacturing, aiming to capture a larger share of the growing biologics CDMO market. This strategic shift builds on its existing infrastructure and regulatory experience, potentially opening new revenue streams and strengthening its competitive position. While financial details are not publicly disclosed, Basic Pharma's focus on expansion and service diversification suggests a trajectory of steady growth. The company's ability to navigate the complexities of biologics manufacturing and attract blue-chip clients will be key to its success in the evolving pharmaceutical outsourcing landscape.

Upcoming Catalysts (preview)

• Q4 2026Completion of biologics manufacturing facility expansion70% success
• Q2 2027Announcement of strategic partnership with a top 20 pharmaceutical company50% success
• Q3 2027First regulatory approval for a biosimilar product manufactured in-house40% success